Epsolay (Benzoyl Peroxide) Patent Expiration, LOE Window & CMS Spending
Epsolay (Benzoyl Peroxide) by Mayne: FDA Orange Book LOE 2041-05-23, 0 AB generics, $489K 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Mayne |
| FDA Application & Pathway | N214510 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2041-05-23 |
| Orange Book Patents (*PED Extensions) | 14 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $489K |
| 2024 Medicare Part D Spend | $463K |
| 2024 Medicaid Spend | $26K |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 60.9% 2-yr change) |